Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 7,741 Shares

Krystal Biotech, Inc. (NASDAQ:KRYS) Director Daniel Janney sold 7,741 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $275.63, for a total value of $2,133,651.83. Following the sale, the director owned 85,096 shares in the company, valued at approximately $23,455,010.48. This trade represents a 8.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Daniel Janney also recently made the following trade(s):

• On Wednesday, February 25th, Daniel Janney sold 700 shares of Krystal Biotech stock. The stock was sold at an average price of $275.00, for a total value of $192,500.00.
• On Tuesday, February 24th, Daniel Janney sold 13,825 shares of Krystal Biotech stock. The stock was sold at an average price of $268.34, for a total value of $3,709,800.50.
• On Tuesday, February 24th, Daniel Janney sold 37,895 shares of Krystal Biotech stock. The shares were sold at an average price of $266.88, for a total value of $10,113,417.60.

Krystal Biotech Stock Performance

Krystal Biotech stock traded up $3.86 during midday trading on Thursday, reaching $276.36. 215,358 shares of the company were exchanged, compared to its average volume of 317,968. The firm’s 50-day simple moving average is $268.29 and its 200-day simple moving average is $213.42. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $298.30. The company has a market capitalization of $8.08 billion, a price-to-earnings ratio of 40.34 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $107.11 million for the quarter, compared to analyst estimates of $105.30 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. On average, analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Krystal Biotech

Large investors have recently modified their holdings of the company. Seven Fleet Capital Management LP acquired a new position in shares of Krystal Biotech in the 4th quarter valued at about $986,000. Pacer Advisors Inc. increased its position in Krystal Biotech by 182.0% during the 4th quarter. Pacer Advisors Inc. now owns 1,712 shares of the company’s stock worth $422,000 after purchasing an additional 1,105 shares in the last quarter. Vident Advisory LLC raised its holdings in Krystal Biotech by 5.4% in the fourth quarter. Vident Advisory LLC now owns 1,494 shares of the company’s stock valued at $368,000 after buying an additional 76 shares during the period. EP Wealth Advisors LLC purchased a new position in Krystal Biotech in the fourth quarter valued at approximately $455,000. Finally, Empowered Funds LLC acquired a new position in Krystal Biotech during the fourth quarter valued at approximately $212,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on KRYS shares. HC Wainwright restated a “buy” rating and set a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Bank of America raised their price target on Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Zacks Research cut Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Chardan Capital increased their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Finally, The Goldman Sachs Group raised their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Krystal Biotech has an average rating of “Moderate Buy” and an average target price of $326.25.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.